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Abstract
Insulin-like growth factor binding protein 7 (IGFBP-7) is the only member of the IGFBP superfamily that binds
strongly to insulin, suggesting that IGFBP-7 may have different functions from other IGFBPs. Unlike other IGFBPs,
the expression and functions of IGFBP-7 in glioma tumors have not been reported. Using cDNA microarray anal-
ysis, we found that expression of IGFBP-7 correlated with the grade of glioma tumors and the overall patient sur-
vival. This finding was further validated by real-time reverse transcription–polymerase chain reaction and Western
blot analysis. We used RNAi to examine the role of IGFBP-7 in glioma cells, inhibiting IGFBP-7 expression by short
interfering RNA transfection. Cell proliferation was suppressed after IGFBP-7 expression was inhibited for 5 days,
and glioma cell growth was stimulated consistently by the addition of recombinant IGFBP-7 protein. Moreover,
glioma cell migration was attenuated by IGFBP-7 depletion but enhanced by IGFBP-7 overexpression and addition.
Overexpression of AKT1 in IGFBP-7–overxpressed cells attenuated the IGFBP-7–promoted migration and further
enhanced inhibition of IGFBP-7 depletion on the migration. Phosphorylation of AKT and Erk1/2 was also inversely
regulated by IGFBP-7 expression. These two factors together suggest that IGFBP-7 can regulate glioma cell mi-
gration through the AKT-ERK pathway, thereby playing an important role in glioma growth and migration.
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Introduction
Insulin-like growth factor (IGF) is a potent mitogen involved in
normal growth and development. In the central nervous system, IGFs
promote the proliferation of oligodendrocytes and myelin synthesis
[1] and are thought to play a critical role in the proliferation of
brain tumors [1]. The growth-promoting and metabolic activities of
IGFs are modulated by insulin-like growth factor binding proteins
(IGFBPs) and their receptors [2,3]. The biological actions of IGFs
may be regulated by IGFBPs either negatively or positively, depending
on the tissue type and the physiological and/or pathological status [4].
Insulin-like growth factor binding proteins are soluble secreted
proteins that bind IGF-I and IGF-II with affinity that is equal to
or greater than those of IGF receptors. The IGFBP family consists
of two groups: 1) high-affinity IGFBPs (i.e., IGFBPs 1-6) and 2)
low-affinity IGFBPs (i.e., IGFBP-related proteins 1-4) [5,6]. The
low-affinity IGFBPs are classified as IGFBP family members by
virtue of their structure homology with the high-affinity IGFBPs. Their
low affinity for IGF in addition to the conserved structure homology
to the IGFBP family leads to the proposal that these IGFBPs may
have unique biological properties independent of their capacity to bind
IGF [7]. Insulin-like growth factor binding protein 7—also known
as IGFBP-related protein 1 (IGFBP-rP1), mac25/angiomodulin,
tumor adhesion factor, and prostacyclin-stimulating factor—is one
of the low-affinity IGFBPs [8]. It is distinct from other low-affinity
IGFBP-rPs in that it can bind strongly to insulin [9]. The expression
of IGFBP-7 is related to tissue type and tumor pathology. IGFBP-7
has been known as a tumor-suppressor gene in prostate and breast
cancers. Detectable IGFBP-7 mRNA levels are lost significantly in
metastatic prostate tissue [10]. Both in vitro and in vivo studies have
shown that overexpression of IGFBP-7 in human prostate cancer
M12 suppresses cell proliferation, colony formation in soft agar,
and tumor formation in male nude mice, suggesting that IGFBP-7
might have a suppressive effect on prostate cancer development
[11,12]. However, using immunohistochemistry to stain prostate
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cancer and benign prostate tissues, Degeorges et al. [5] showed that
IGFBP-7 was expressed in invasive prostate neoplasms but not typ-
ically in normal secretory or benign prostatic hyperplasia epithelium.
Furthermore, low IGFBP-7 was also found to be associated with
poorly differentiated breast cancer tumors and higher-stage disease
when immunohistochemical staining and microarray were used to
identify IGFBP-7 expression in the tumor cells [14]. Expression of
IGFBP-7 has been found to be up-regulated in human colorectal
cancer [15] and glioma cell lines [16]. So far, there is limited under-
standing of the biological and mechanistic functions of IGFBP-7 in
different cancers, especially gliomas.
In this paper, we report the association of IGFBP-7 expression
levels with glioma grade and outcome. We investigated the roles of
IGFBP-7 in glioma cell growth and migration, as well as the molecu-
lar mechanisms involved.
Materials and Methods
Materials
Polyclonal anti–IGFBP-rP1 antibody and recombinant IGFBP-
rP1 protein were purchased from R&D Systems, Inc. (Minneapolis,
MN). silMPORTER short interfering RNA (siRNA)/plasmid DNA
transfection reagent was purchased from Upstate, Inc. (Charlottesville,
VA). Transwell Permeable Supports were purchased from Corning
Life Science (Acton, MA). A Matrigel Invasion Chamber was obtained
from BD Discovery Labware (Bedford, MA). SeaPlaque Agarose
was purchased from Cambrex (Rockland, MN), and CytoMatrix
Cell Adhesion strips were purchased from Chemicon International
(Temecula, CA).
Glioma Cells
The glioma cell lines, A172, U87, U251, LN18, LNZ308, and
LN443, purchased from American Type Culture Collection (Manassas,
VA), were grown on tissue culture dishes in medium consisting of
Dulbecco’s modified Eagle’s medium (DMEM) containing 10%
fetal bovine serum (FBS), 2 mM glutamine, 50 U/ml penicillin,
and 0.05 mg/ml streptomycin.
Tumor Samples
Glioma tumor samples from 192 patients were obtained from the
Glioma Biorepository at Henry Ford Hospital, Detroit, MI. All tumor
samples were obtained with written consent in accordance with institu-
tional guidelines. Tumor histologies included 81 glioblastomas multi-
forme (GBMs), 49 oligodendrogliomas, 28 astrocytomas, 11 mixed
gliomas, and 21 nontumor brain tissues obtained from epilepsy surgery.
All tissues had been freshly frozen and stored at −80°C.
Microarray Construction
We used an array, constructed at the Neuro-Oncology Branch of
the National Cancer Institute/National Institute of Neurological Dis-
orders and Stroke, containing the 28,896 Research Genetics cDNAs
(15,935 of them have been sequence-verified) and an additional
5664 Cancer Genome Anatomy Project (CGAP) sequence-verified
cDNAs obtained through data mining of the CGAP databases. The
clones we selected were those related to genes that had been described
previously as potentially important for cancer or glioma development,
such as genes involved in invasion, angiogenesis, and transformation.
We also selected a series of clones that have been shown previously
to be over- or underexpressed highly in the glioma SAGE database.
Finally, we incorporated a number of cDNA clones that were obtained
by screening approximately 20 glioma cDNA libraries for highly rep-
resented and/or unusual transcripts. The arrays were printed using
an OmniGrid Microarrayer (GeneMachines, San Carlos, CA) on
poly-L-lysine–coated glass slides.
RNA Preparation and Microarray Experiments
Total RNA was isolated using TRIzol (Life Technologies, Rockville,
MD) according to the manufacturer’s instructions. The RNA was
further purified using RNeasy Mini kit (Qiagen, Inc., Valencia, CA).
Total RNA was then linearly amplified one round as described previ-
ously [1]. Amplified RNA (1 μg) was reverse-transcribed and labeled
directly with Cy3-dUTP and Cy5-dUTP using a cDNA labeling kit
according to manufacturer’s instructions (Amersham, Inc., Piscataway,
NJ). Tissue sample RNA was labeled with Cy5, and Universal Human
Reference RNA (Stratagene, La Jolla, CA) was labeled with Cy3.
Labeled cDNA were hybridized to the 34,561-feature glass cDNA
microarrays overnight at 42°C with 25% formamide. The arrays were
scanned on a GenePix 4000A microarray scanner (Axon Instruments,
Foster City, CA) to generate TIFF images. GenePix pro 3.0 microarray
analysis software (Axon Instruments) was used to measure fluores-
cence signals. All of the array data were deposited in the National Can-
cer Institute Center for Information Technology microarray database
(http://nciarray.nci.nih.gov/).
Short Interfering RNA Transfection
Short interfering RNA duplexes were synthesized and purified by
Dharmacon (Lafayette, CO). We used a pool of four IGFBP-7 siRNA
duplexes that were also obtained from Dharmacon. Transfection of
siRNA was done using 100-nM IGFBP-7 or scrambled control siRNA
and silMPORTER kit (Upstate, Inc.) according to the manufacturer’s
instructions. Protein levels of IGFBP-7 were determined using Western
blot analysis.
Proliferation Analysis
The cell lines, LN18 and LN443, expressing very low or medium
levels of IGFBP-7 protein and mRNA, were grown in DMEM/10%
FBS medium containing 1 μg/ml of IGFBP-7 recombinant protein
for 6 days. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay was applied to analyze cell proliferation at days 0,
1, 3, and 6 of the treatment. Briefly, 1 × 103 cells were planted into
96-well plates and grown overnight in DMEM supplemented with
10% FBS and cultured at 37°C with 5% CO2. At day 0, one 96-well
plate was used for the MTT assay. Meanwhile, the medium of the
other 96-well plates was changed with DMEM supplemented with
10% FBS containing 1 μg/ml of IGFBP-7 recombinant protein.
Fresh medium was added every day up to day 6 of the treatment.
Cell proliferation was analyzed with MTT at days 1, 3, and 6.
Transwell Migration Assay
Corning Costar Transwell plates (8 μM) were pretreated according
to the manufacturer’s instructions. The cells that had been trans-
fected with IGFBP-7 siRNA or control siRNA for 3 days were tryp-
sinized, collected in DMEM supplemented with 10% FBS, and
centrifuged at 1200 rpm for 5 minutes at 4°C. Cell pellets were sus-
pended in DMEM supplemented with 10% FBS medium for count-
ing. Cell concentration was adjusted to 4 × 105 cells/ml, and 250 μl
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of cell suspension was plated into each membrane chamber of a
24-well Transwell plate, with 400 μl of medium. Plates were incu-
bated at 37°C under 5% CO2 for 2 days. Migrated cells were stained
and counted as reported previously [18].
Scratch Assay
Parental or transfected cells (1 × 106 cells per well) were seeded
into a 12-well plate and cultured overnight under 5% CO2 at 37°C.
When the cells were 80% confluent, a straight scratch was gently
made through the central axis of the plate using a micropipette tip.
The plates were rinsed with Hanks solution, and serum-free DMEM
was added. After a 24-hour incubation, the distance of cells migrat-
ing into the acellular area created by scratching was measured in ran-
domly selected visual fields (n = 9) at a magnification of ×20 using
an inverted microscope. The measurement was repeated three times
for each group of cells. The percentage of migration was determined
by dividing the migrated distance by the scratched distance.
Cell Growth Analysis
A172 cells (1 × 105) in 500 μl of medium were plated onto 12-well
plates a day before transfection. Insulin-like growth factor binding
protein 7 and control siRNA were transfected using silMPORTER
kit from Upstate, Inc. Cell number was counted on days 3 and
5 of transfection. On the day the assay was performed, 50 μl of
10 mM EDTA was added to each well and incubated at 37°C for
2 minutes. Cells were suspended with 1 × PBS (450 μl), and cell
suspension was collected in a 5-ml tube. The remaining cells in
the well were washed with 1 × PBS (500 μl) and collected in the
same tube. The cell suspension was kept on ice and then counted
through a microscope with Trypan blue staining.
Western Blot Analysis
Total cell lysates were prepared in a RIPA buffer (50 mM Tris-HCl
pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate,
and 0.1% SDS) with protease inhibitors (Roche Diagnostics, Basel,
Switzerland). Electrophoresis was performed on either 10% or 12%
SDS-PAGE (Bio-Rad, Hercules, CA) and transferred onto PVDF
Plus membrane (MSI, Inc., Minnetonka, MN) using the Bio-Rad
Mini Protean II transfer system.
RNA Extraction
Total RNA was isolated from nontumor brain tissues (i.e., from
epilepsy surgeries and postmortem from patients with causes of
death other than brain disease) and brain tumor samples (i.e., glio-
blastomas, astrocytomas, and oligodendrogliomas) using an RNeasy
lipid tissue mini RNA-isolation kit (Qiagen) following the manufac-
turer’s instructions. The quality of the RNA samples was determined
by measuring their absorbance at 260 nm as well as by electrophoresis
through agarose gels and staining with ethidium bromide, and the 18S
and 28S RNA bands were visualized under UV.
Reverse Transcriptional Reaction
Reverse transcription of RNA was done in a final volume of
20 μl containing 13 reverse transcription–polymerase chain reaction
(RT-PCR) buffer (500 mM each deoxynucleotide triphosphate,
3 mM MgCl2, 75 mM KCl, 50 mM Tris-HCl, pH 8.3), 10 units of
RNasin RNase inhibitor (Promega Corp., Madison, WI), 10 mM
DTT, 50 units of Superscript II RNase H2 reverse transcriptase (Life
Technologies, Inc., Gaithersburg, MD), 1.5 mM random hexamers
(Pharmacia, Uppsala, Sweden), and 1 μg of total RNA. The sam-
ples were incubated at 20°C for 10 minutes and at 42°C for 30 min-
utes, and the reverse transcriptase was inactivated by heating at 99°C
for 5 minutes and cooling at 5°C for 5 minutes.
Real-time PCR Amplification
All PCRs were performed using an ABI Prism 7000 Sequence
Detection System (Perkin-Elmer Applied Biosystems, Foster City,
CA). Primers for the IGFBP-7 gene were chosen with the assistance
of the computer program, Vector NT. We conducted BLASTN
searches against refSeq_rna to confirm the total gene specificity of
the nucleotide sequences chosen for the primers and the absence
of DNA polymorphisms. To avoid amplification of contaminating
genomic DNA, the two primers were placed in two different exons.
For each PCR run, 8 μl of 30-fold diluted cDNA was mixed with 2 μl
of primer mixture (10 μM per primer) and 10 μl of Platinum SYBR
Green qPCR SuperMix UDG with ROX (No. 11744; Invitrogen,
Carlsbad, CA) on ice. The thermal cycling conditions consisted of
an initial denaturation step at 95°C for 4 minutes, 45 cycles at 95°C
for 30 seconds, 60°C for 30 minutes, and 70°C for 1 minute and fin-
ished with incubation at 72°C for 7 minutes.
Statistical Analysis
The results are presented as the mean ± SD. Data were analyzed
using analysis of variance and Student’s t test to determine the level of
significance between the different groups.
Results
Expression of IGFBP-7 in Glioma Tumors
The expression of IGFBP-7 has been found in the literature to be
down-regulated in prostate and breast cancer cells [11,12,14]. In
contrast, our microarray analysis of glioma patients’ cDNA showed
that IGFBP-7 was highly up-regulated in GBM compared to non-
tumor brain tissue (Figure 1A). To verify the microarray results, we
randomly picked samples from our tumor bank for quantitative real-
time RT-PCR analysis to verify the range of expression of IGFBP-7.
Its expression by quantitative real-time RT-PCR in tumors confirmed
the microarray results (Figure 1C ). A P < .05 supported our hypothe-
sis that up-regulation of IGFBP-7 expression is statistically signifi-
cant in GBM samples. We also randomly picked GBM specimens
for Western blot analysis not necessarily matched to those included
in microarray analysis. Western blot analysis further demonstrated
IGFBP-7 protein expression in GBM specimens. As shown in Fig-
ure 2A, IGFBP-7 protein was strongly expressed in GBM specimens
but not in nontumor brain tissues. Therefore, the results of RT-PCR
and Western blot analysis increased the number of tumors examined
to support the microarray results. Owing to the lack of a robust
antibody for IGFBP-7 immunohistochemistry staining in human
brain specimens, we analyzed IGFBP-7 expression in primary tumor
culture. As shown in Figure 2C , IGFBP-7 was expressed in the pri-
mary cultured cells. In addition, we also analyzed the IGFBP-7 ex-
pression in GBM xenografts in nude rats that were implanted with
primary cultured GBM cells using Western blot analysis as well as
RT-PCR of IGFBP-7 mRNA with human-specific primers. Both
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analyses showed IGFBP-7 expression in human glioma cells but not
rat brains (data not shown). These data together suggested that
IGFBP-7 was overexpressed in GBM specimens.
Moreover, statistical analysis of patient survival showed that the
expression of IGFBP-7 correlated inversely with overall GBM patient
survival rates (Figure 1B), that is, the GBM patients with high levels
of IGFBP-7 (i.e., the threshold for IGFBP-7 up-regulation was two-
fold or higher) had shorter survival than those with intermediate
levels (i.e., IGFBP-7 expression in the tumors falls within the two-
fold change compared to the nontumor samples). In addition, using
real-time RT-PCR and Western blot analysis, we found that IGFBP-7
was expressed in different glioma cell lines (Figures 1D and 2B).
Influence of IGFBP-7 on Glioma Cell Growth
According to the Western blot analysis of the glioma cell lines, we
chose A172 cells for our experiments owing to their relatively high
level of IGFBP-7 expression. We used RNA interference to diminish
the expression of IGFBP-7 in A172 cells. The Western blot assay
shown in Figure 2A suggests that more than 95% of IGFBP-7 protein
expression in these cell lines was inhibited by siRNA transfection. Cell
growth analysis showed that cell growth was significantly suppressed
by IGFBP-7 gene RNA interference after IGFBP-7 siRNA had been
transfected for 5 days (Figure 3A).
Because IGFBP-7 is a secreted protein, we treated cells with IGFBP-7
recombinant protein to examine whether IGFBP-7 can stimulate
cell proliferation. LN18 and LN443 showed lower levels of IGFBP-7
expression when analyzed by real-time RT-PCR and Western blot
assay (Figures 1D and 2B). The addition of IGFBP-7 recombinant
protein in cell culture medium of these cells stimulated the cell pro-
liferation significantly (Figure 3B). Results from the addition and de-
pletion of IGFBP-7 suggest that IGFBP-7 plays an important role
in the regulation of glioma cell growth and proliferation. In addition,
the apoptosis assay (Annexin-V staining) showed that depletion of
IGFBP-7 expression in glioma cells did not induce cell apoptosis
(data not shown). Taken together, these data suggest that IGFBP-7
regulates glioma cell proliferation and growth but not cell survival.
Figure 1. Insulin-like growth factor binding protein 7 is up-regulated in gliomas, and its expression correlates with overall patient survival.
(A) Microarray analysis of IGFBP-7 mRNA level in different grades of glioma tissues. Tumor specimens included 89 glioblastomas
(GBMs), 49 oligodendrogliomas (Oligo), 28 astrocytomas (Astro), and 21 nontumor brain tissues obtained from epilepsy surgery (non-
tumor). The t test analysis shows that P < .005 for GBM versus nontumor, oligodendroglioma versus nontumor, and astrocytoma versus
nontumor. Different color bars show the analysis using different probes. (B) Probability of GBM patient survival and IGFBP-7 expression
level. The yellow line indicates the survival of GBM patients with intermediate levels of IGFBP-7 mRNA (i.e., IGFBP-7 expression in the
tumors falls within the two-fold change compared to the nontumor samples) in specimens; the red line indicates the survival of GBM
patients with high levels of IGFBP-7mRNA (i.e., the threshold for IGFBP-7 up-regulation of two-fold or higher) in specimens; and the blue
line indicates the overall GBM patient survival rate. The number of patients with up-regulated IGFBP-7 expression in the group is 74,
whereas the number of patients with intermediate levels of IGFBP-7 is 13 and two tumors showed down-regulation of IGFBP-7 expres-
sion (i.e., two-fold or less, shown in green line). The t test analysis showed that the P value between the intermediate and up-regulated
levels is < .01. (C) Real-time RT-PCR data validated that IGFBP-7 expression level correlates to tumor grades. The samples used in this
analysis did not have to be the same as those used for the microarray assay and were randomly selected from our tumor bank. The t test
analysis shows that P < .05 for GBM versus nontumor and for oligodendroglioma versus nontumor. (D) IGFBP-7 mRNA expression in
different glioma cell lines. Seven glioma cell lines were analyzed by real-time PCR. The IGFBP-7 expression level in these cells is pre-
sented compared with the housekeeping gene S12.
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IGFBP-7 Intervenes in the Migration of Glioma Cells
Through Regulating AKT and Erk1/2 Activation
Cell migration assays were conducted on uncoated transwell plates
(i.e., they were not coated with extracellular matrix proteins) and
uncoated six-well plates using scratch assay. After IGFBP-7 was
knocked down, glioma cell migration decreased. After 48 hours of
plating the transfected cells into the Transwell plates, we counted
the migrated cells. The results were presented as the mean migrated
cell number ± standard error. We used Student’s t test to determine
whether migration differs significantly between IGFBP-7–depleted
cells and control cells. As shown in Figure 4A, compared to control
transfection, migrated A172 cells of IGFBP-7–depleted cells were de-
creased approximately 44%. Figure 4B shows the same migration
analyzed with scratch assay. The data confirmed that the two assays
are consistent.
To further confirm the impact of IGFBP-7 on glioma cell migra-
tion, IGFBP-7 was added into the growth medium or overexpressed
in glioma cells. Shown in Figure 4, C and D, the addition or overex-
pression of IGFBP-7 promoted the migration of LN18 and LN443
cells that have low levels of endogenous expression of this protein.
Taken together, the data suggested that IGFBP-7 can mediate glioma
cell migration.
Insulin-like growth factor binding proteins can compete with
IGF-R to bind to IGFs to prolong the half-life of IGFs. Previous
published data suggested that IGF-I or IGF-II can regulate cell
growth, motility, and other biological processes through regulating
the activation of PI3K/AKT and MEK/ERK pathways. To verify
whether IGFBP-7 can mediate the activation of AKT and ERK1/2,
we analyzed the phosphorylation of ERK1/2 and AKTafter IGFBP-7
was added into the cell medium up to 6 hours. Western blot analysis
Figure 3. Insulin-like growth factor binding protein 7 mediates glioma cell growth. (A) A172 cell growth after IGFBP-7 was silenced for 3
and 5 days. Open columns show the cell growth of control siRNA transfected cells. Black columns represent the cell growth of IGFBP-7–
depleted cells. Significance is as follows: *P < .05, **P < .01. Western blot analysis confirmed the depletion of IGFBP-7 in IGFBP-7–
silenced A172 cells. To silence IGFBP-7 expression in glioma cells, 100 nM IGFBP-7 or control siRNA was transfected into A172 cells
using silMPORTER kit. Total cell lysates were collected in RIPA buffer after 72 hours of transfection. Serum-free medium was also
collected. Total cell lysates (30 μg) or serum-free cell culture medium was separated by 12% SDS-PAGE and analyzed for IGFBP-7 ex-
pression. (B) LN18 and LN443 cells grew in the DMEM containing 1 μg/ml IGFBP-7 for 6 days. Fresh medium was added every day to
keep the concentration of IGFBP-7 consistent. Cell growth was analyzed using Trypan Blue staining and counting.
Figure 2. Insulin-like growth factor binding protein 7 expression in
GBM specimens and glioma cell lines. (A) Expression of IGFBP-7
protein in GBM and nontumor specimens was analyzed by Western
blot. Protein extracts (30 μg) from GBM specimens and nontumor
specimens were separated by 12% SDS-PAGE and were trans-
ferred to PVDF membrane. Immunoblot analysis was performed
with anti–IGFBP-7 antibody and antiactin antibody in the same
membrane. (B) Expression of IGFBP-7 protein in glioma cell lines
was studied by Western blot analysis. Total cell lysates (30 μg)
were separated by 12% SDS-PAGE. (C) Expression of IGFBP-7 pro-
tein in primary cultured GBM tumor cells (passages were <5) was
analyzed by Western blot assay.
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(Figure 5) showed that the levels of ERK1/2 and AKT phosphory-
lation varied with the incubation time of glioma cells in IGFBP-7–
added medium. To further verify the effect of AKT activation on
IGFBP-7–regulated glioma cell migration, we overexpressed AKT
in IGFBP-7–silenced A172 and IGFBP-7–overexpressed LN18.
The migration assay (Figure 6) showed that overexpression of AKT
further enhanced the decreased migration caused by IGFBP-7 silenc-
ing but overcame the IGFBP-7–promoted cell migration in IGFBP-7
overexpressed cells. These data together suggest that IGFBP-7 pro-
moted glioma cell migration through regulating the AKT and
ERK1/2 signal transductions.
Discussion
Although RT-PCR [22] detected the expression of IGFBP-7mRNA
in 87% of established glioma cell lines, the expression and function
of IGFBP-7 in primary glioma tumor specimens have not yet been
studied. The biological function and expression of IGFBP-7 seems
to be diverse and cell type– or host-environment–specific. Subtrac-
tive hybridization assays have shown that IGFBP-7 was preferentially
expressed in normal leptomeningeal cells compared with menin-
giomas [2]. In situ hybridization studies of IGFBP-7 expression in
normal prostate tissue versus prostate tumors have shown that a
marked decrease in IGFBP-7 expression was associated with increas-
ing malignancy [3]. Furthermore, a prostatic carcinoma cell line sta-
bly transfected with IGFBP-7 cDNA showed poor tumorigenicity
in both in vitro and in vivo assays compared with vector controls
[4]. These observations suggest that IGFBP-7 has a potential tumor-
suppressive function. Contradictory to these findings, Degeorges et al.
[5] used immunohistochemical staining to analyze the location of
IGFBP-7 in prostate cancer. They found that the most intense staining
was observed in nerves, whereas smooth muscle cells in the prostate
stained weakly. Lymphocytes were always negative. When normal
Figure 4. Insulin-like growth factor binding protein 7 regulates glioma cell migration. (A) Migration assay of IGFBP-7–depleted A172 and
LNZ308 glioma cells was conducted on Corning Costar Transwell plates (8 μM). Cells (1 × 105) that were transfected with IGFBP-7 or
control siRNA for 3 days were plated into each membrane chamber of a 24-well Transwell plate with 400 μl of medium. Plates were
incubated at 37°C under 5% CO2 for 2 days before migrating cells were counted. The data represent the average of three independent
experiments with triplicate samples in each experiment. The significance is P < .01. (B) Migration of IGFBP-7–depleted A172 and
LNZ308 glioma cells was analyzed using scratch assay. The distance of migrated cells from the scratched point was measured ran-
domly. The percentage of migration was determined by dividing the migrated distance by the scratched distance. The cells that were
transfected with IGFBP-7 or control siRNA for 3 days were plated into a 12-well plate to 80% confluence before the day of assay. The
scratched cells were grown in serum-free medium for 24 hours before analyzing the migration. (C) The effect of IGFBP-7 on the migra-
tion of glioma cells that have low endogenous levels of this protein was analyzed by adding IGFBP-7 recombinant protein (0, 1, 5 μg/ml)
into the growth medium of LN18 and LN443 cells. The cells were grown in serum-free and IGFBP-7–enriched medium after scratching.
The migration was analyzed after 24 hours. (D) The IGFBP-7–mediated migration was analyzed with IGFBP-7–overexpressed LN18
or LN443 cells. Scratch assay was conducted as described in panel (B). Significance values compared to control cells are as follows:
*P < .05, **P < .01.
Figure 5. Activation of AKT and ERK1/2 in IGFBP-7–treated cells.
The LN18 cells were treated with IGFBP-7 recombinant protein
(1 μg/ml) at several time points as seen in this figure. The total
cell lysates (30 μg) were collected for Western blot analysis using
anti–phosphorylated AKT (Ser473), anti-AKT, anti–phosphorylated
ERK1/2, and anti–ERK1/2 antibodies.
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prostatic secretory epithelium was present, staining was usually ab-
sent. The lining secretory epithelium stained positively in 0 (0%) of
12 cases of benign prostatic hyperplasia, 57 (90.5%) of 63 primary
adenocarcinomas, and 7 (100%) of 7 prostate cancer metastases. Pros-
tatic intraepithelial neoplasia showed a similar pattern of staining to
that observed for the invasive tumors. Although prostate cell lines such
as LNCap and C4-2 have no IGFBP-7 expression, the researchers
found that tumor xenografts generated by direct intraosseous injection
of LNCaP or C4-2 to bone marrow space resulted in tumors that
stained positively for IGFBP-7, suggesting that the expression of
IGFBP-7 can be induced in human prostate cancer cell lines in vivo
on interaction with an appropriate host environment. In addition,
Creighton et al. [6] also showed that IGFBP-7 was up-regulated in
tumor xenografts generated by the implantation of human lung adeno-
carcinoma (A549) cells. In agreement with these results, we found that
IGFBP-7 was highly overexpressed in glioma tissues. Our RT-PCR
and Western blot assay data suggest that IGFBP-7 expression corre-
sponds to tumor grade at both protein and mRNA levels. Together,
these results suggest that IGFBP-7 plays different roles in different
organs or host environments, a finding which is common in the
IGFBP family. For instance, IGFBP-2 has also been ascribed properties
of both suppressor and enhancer of cell proliferation. In small cell lung
cancer cells, soluble IGFBP-2 inhibited IGF-dependent DNA synthe-
sis [7]. In nontransformed IEC-6 cells, exogenous IGFBP-2 resulted in
decreased proliferation [8], whereas expression of antisense IGFBP-2
resulted in growth stimulation [9]. In contrast, a positive correlation
between IGFBP-2 level and cell proliferation has been observed in
human colon carcinoma [10], in conjunction with a positive correla-
tion between tumor grade and level of IGFBP-2 in colon [11], adre-
nal [12], prostate [13], and central nervous system tumors [14,15].
Similarly, IGFBP-5 has been associated with both the inhibition and
stimulation of cell growth with variable cell–type specificity [16,17].
One of the biological attributes of glioma cell progress is the persis-
tent formation of new vessels. A previous report of immunohistochemi-
cal staining of various tumor tissues indicated that IGFBP-7 seems to
specifically accumulate in new blood vessels in various human cancer
tissues including GBM specimens but not in those of normal tissues
and capillary tube–like structures of cultured vascular endothelial cells
[18]. A recently published paper showed similar findings, i.e., IGFBP-7
was exclusively associated with laminin-stained GBM vessels but was
not observed in the vessels from nonmalignant brain [19]. These re-
sults indicate that IGFBP-7 may correlate with glioma cell progression.
On the basis of the fact that IGFBP-7 is secreted protein, these ob-
servations and our data suggest that IGFBP-7 can promote glioma cell
migration and growth along the newly formed tumor vessels.
Some research has suggested that IGFBP-7 has the ability to be
involved in signal transduction in both IGF-dependent and IGF-
independent pathways [20,21]. A previous study [22] showed that
phosphorylated Erk and Akt were increased in the M12 and LNCaP
transfected IGFBP-7 cells and that inhibition of PI-3 kinase results in
a marked decrease in viability of the M12–IGFBP-7 cells compared
to M12 controls, suggesting that IGFBP-7 could regulate prostate
cancer cell through the PI3K/AKT pathway. Similarly, we showed
the activation of AKT and ERK1/2 in IGFBP-7–treated glioma cells.
Furthermore, we analyzed the impact of IGFBP-7/AKTon the glioma
cell migration. Our data suggested that IGFBP-7 promoted glioma
cell migration through down-regulating the signaling of AKT. Al-
though previous studies indicated that AKT activation induces cancer
cell invasion, recent studies that agree with our finding suggest that
AKT1 can block the cell migration and invasion. Irie et al. [23]
showed that down-regulation of AKT1 enhanced the migration of
IGF1-receptor–overexpressing cells induced by EGF. In addition, Irie
et al. [23] also found that enhanced ERK1/2 activation is necessary for
the migration induced by AKT1 down-regulation and that down-
regulation of AKT1 enhanced ERK1/2 activation. Our data showed
that ERK1/2 activation increased with the addition of IGFBP-7 re-
combinant protein in medium up to 0.5 hours and then decreased
lower than the basal level and then increased again after incubation
for 8 hours. The activation of AKTwas decreased whereas phosphory-
lation of ERK1/2 was enhanced. Together, it implies that IGFBP-7
may regulate glioma cell growth and tumorigenesis through signals
that are regulated by the AKT/PKB pathway.
In conclusion, we demonstrate for the first time that expression of
IGFBP-7 correlates with tumor (i.e., glioma) grade and overall GBM
patient survival and that IGFBP-7 mediates glioma cell growth and
migration through regulating AKT and ERK1/2 activation.
Acknowledgments
The authors thank Sandra Rempel for her invaluable discussion
and comments. The authors acknowledge the support of the Glioma
Figure 6. The effect of AKT on IGFBP-7–mediated migration. (A)
Overexpression of AKT1 in IGFBP-7–depleted cells enhanced
the inhibition of IGFBP-7 depletion on cell migration. AKT1 plas-
mid and IGFBP-7 siRNA were cotransfected into A172 cells using
silMPORTER siRNA and plasmid DNA Transfection Reagent
(Upstate). After 48 hours of transfection, cells were plated in a
24-well plate, and migration was analyzed using scratch assay.
Western blot analysis of IGFBP-7, phosphorylation of AKT and
Erk1/2, and total AKT and Erk1/2 expression in total cell lysates is
included. (B) Overexpression of AKT1 in IGFBP-7–overexpressed
cells inhibited the promoted migration by IGFBP-7 overexpression.
AKT1 and IGFBP-7 plasmids were cotransfected into LN18 cells
using Lipofectamine 2000 reagent (Invitrogen). The migration assay
was conducted on Corning Costar Transwell plates (8 μM). The ex-
pression of IGFBP-7 in cell lysates was analyzed by Western blot
assay as shown in the figure. The effect of IGFBP-7 and AKT expres-
sion on the activation of AKT and Erk1/2 was analyzed by Western
blot assay. The significance between the transfected cells and con-
trol cells are as follows: ***P < .001, **P < .01, and *P < .05.
Neoplasia Vol. 10, No. 12, 2008 IGFBP-7, GBM Cell Growth, and Migration Jiang et al. 1341
Molecular Diagnostics Initiative, neuro-oncology branch NCI/NINDS
for the microarray data.
References
[1] Marko NF, Frank B, Quackenbush J, and Lee NH (2005). A robust method for
the amplification of RNA in the sense orientation. BMC Genomics 6 (1), 27.
[2] Murphy M, Pykett MJ, Harnish P, Zang KD, and George DL (1993). Identi-
fication and characterization of genes differentially expressed in meningiomas.
Cell Growth Differ 4 (9), 715–722.
[3] Hwa V, Tomasini-Sprenger C, Bermejo AL, Rosenfeld RG, and Plymate SR
(1998). Characterization of insulin-like growth factor–binding protein–related
protein-1 in prostate cells. J Clin Endocrinol Metab 83 (12), 4355–4362.
[4] Sprenger CC, Damon SE, Hwa V, Rosenfeld RG, and Plymate SR (1999).
Insulin-like growth factor binding protein–related protein 1 (IGFBP-rP1) is a
potential tumor suppressor protein for prostate cancer. Cancer Res 59 (10),
2370–2375.
[5] Degeorges A, Wang F, Frierson HF Jr, Seth A, Chung LW, and Sikes RA (1999).
Human prostate cancer expresses the low affinity insulin-like growth factor
binding protein IGFBP-rP1. Cancer Res 59 (12), 2787–2790.
[6] Creighton CJ, Bromberg-White JL, Misek DE, Monsma DJ, Brichory F, Kuick
R, Giordano TJ, Gao W, Onenn GS, Webb CP, et al. (2005). Analysis of tumor-
host interactions by gene expression profiling of lung adenocarcinoma xenografts
identifies genes involved in tumor formation. Mol Cancer Res 3 (3), 119–129.
[7] Reeve JG, Morgan J, Schwander J, and Bleehen NM (1993). Role for mem-
brane and secreted insulin-like growth factor–binding protein-2 in the regula-
tion of insulin-like growth factor action in lung tumors. Cancer Res 53 (19),
4680–4685.
[8] Park JH, McCusker RH, Vanderhoof JA, Mohammadpour H, Harty RF, and
MacDonald RG (1992). Secretion of insulin-like growth factor II (IGF-II) and
IGF-binding protein-2 by intestinal epithelial (IEC-6) cells: implications for
autocrine growth regulation. Endocrinology 131 (3), 1359–1368.
[9] Corkins MR, Vanderhoof JA, Slentz DH, MacDonald RG, and Park JH (1995).
Growth stimulation by transfection of intestinal epithelial cells with an antisense
insulin-like growth factor binding protein-2 construct. Biochem Biophys Res
Commun 211 (3), 707–713.
[10] Hoeflich A, Yang Y, Huber S, Rascher W, Koepf G, Blum WF, Heinz-Erian P,
Kolb HJ, and Kiess W (1996). Expression of IGFBP-2, -3, and -4 mRNA
during differentiation of Caco-2 colon epithelial cells. Am J Physiol 271 (5 Pt 1),
E922–E931.
[11] Renehan AG, Jones J, Potten CS, Shalet SM, and O’Dwyer ST (2000). Elevated
serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients
with colorectal cancer. Br J Cancer 83 (10), 1344–1350.
[12] Boulle N, Baudin E, Gicquel C, Logie A, Bertherat J, Penfornis A, Bertagna X,
Luton JP, Schlumberger M, and LeBouc Y (2001). Evaluation of plasma insulin-
like growth factor binding protein-2 as a marker for adrenocortical tumors. Eur J
Endocrinol 144 (1), 29–36.
[13] Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldwasser B,
and Karasik A (1993). Serum insulin-like growth factor–binding protein-2
(IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate can-
cer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 77
(1), 229–233.
[14] Unterman TG, Glick RP, Waites GT, and Bell SC (1991). Production of
insulin-like growth factor–binding proteins by human central nervous system
tumors. Cancer Res 51 (11), 3030–3036.
[15] Sallinen SL, Sallinen PK, Haapasalo HK, Helin HJ, Helen PT, Schraml P,
Kallioniemi OP, and Kononen J (2000). Identification of differentially expressed
genes in human gliomas by DNA microarray and tissue chip techniques. Cancer
Res 60 (23), 6617–6622.
[16] Butt AJ, Dickson KA, McDougall F, and Baxter RC (2003). Insulin-like growth
factor–binding protein-5 inhibits the growth of human breast cancer cells
in vitro and in vivo. J Biol Chem 278 (32), 29676–29685.
[17] McCaig C, Perks CM, and Holly JM (2002). Signalling pathways involved in
the direct effects of IGFBP-5 on breast epithelial cell attachment and survival.
J Cell Biochem 84 (4), 784–794.
[18] Golembieski WA, Thomas SL, Schultz CR, Yunker CK, McClung HM, Lemke
N, Cazacu S, Barker T, Sage EH, Brodie C, et al. (2008). HSP27 mediates
SPARC-induced changes in glioma morphology, migration and invasion. Glia
56 (6), 1061–1075.
[19] Pen A, Moreno MJ, Martin J, and Stanimirovic DB (2007). Molecular markers
of extracellular matrix remodeling in glioblastoma vessels: microarray study of
laser-captured glioblastoma vessels. Glia 55 (6), 559–572.
[20] Burger AM, Leyland-Jones B, Banerjee K, Spyropoulos DD, and Seth AK
(2005). Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer. Eur J
Cancer 41 (11), 1515–1527.
[21] Oh Y (1998). IGF-independent regulation of breast cancer growth by IGF
binding proteins. Breast Cancer Res Treat 47 (3), 283–293.
[22] Plymate SR, Haugk KH, Sprenger CC, Nelson PS, Tennant MK, Zhang Y,
Oberley LW, Zhong W, Drivdahl R, and Oberley TD (2003). Increased man-
ganese superoxide dismutase (SOD-2) is part of the mechanism for prostate
tumor suppression by Mac25/insulin–like growth factor binding-protein–related
protein-1. Oncogene 22 (7), 1024–1034.
[23] Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P, Kothari N,
Natesan S, and Brugge JS (2005). Distinct roles of Akt1 and Akt2 in regulat-
ing cell migration and epithelial-mesenchymal transition. J Cell Biol 171 (6),
1023–1034.
1342 IGFBP-7, GBM Cell Growth, and Migration Jiang et al. Neoplasia Vol. 10, No. 12, 2008
